Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
79.45 USD | +1.62% | +1.43% | -55.86% |
03:10pm | Generation Bio to Lay Off 40% of Staff in Bid to Extend Cash Runway Into H2 2027 | MT |
01:34pm | Canaccord Genuity Starts Moderna With Hold Rating, Price Target is $82 | MT |
Financials (USD)
Sales 2023 * | 6,493 M | Sales 2024 * | 4,511 M | Capitalization | 29.81 B |
---|---|---|---|---|---|
Net income 2023 * | -5,412 M | Net income 2024 * | -2,319 M | EV / Sales 2023 * | 3,77x |
Net cash position 2023 * | 5,347 M | Net cash position 2024 * | 3,795 M | EV / Sales 2024 * | 5,77x |
P/E ratio 2023 * | -5,69x | P/E ratio 2024 * | -12,8x | Employees | 3,900 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 90.37% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +2.05% | ||
1 week | +2.06% | ||
Current month | +5.03% | ||
1 month | +7.71% | ||
3 months | -31.22% | ||
6 months | -38.10% | ||
Current year | -55.58% |
1 week
75.66
81.12

1 month
62.55
81.12

Current year
62.55
207.51

1 year
62.55
217.25

3 years
62.55
497.49

5 years
11.54
497.49

10 years
11.54
497.49

Managers | Title | Age | Since |
---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 50 | 2011 |
James Mock
DFI | Director of Finance/CFO | 46 | 2022 |
Stephen Hoge
PSD | President | 47 | 2012 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 64 | 2018 |
Director/Board Member | 73 | 2020 | |
Francois Nader
BRD | Director/Board Member | 66 | 2019 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.10% | 5 M€ | -19.87% | ||
5.66% | 0 M€ | 0.00% | - | |
5.54% | 12 M€ | -21.64% | ||
4.69% | 2 M€ | 0.00% |
Date | Price | Change | Volume |
---|---|---|---|
23-11-29 | 79.22 | +1.33% | 1 352 210 |
23-11-28 | 78.18 | +0.59% | 2,240,038 |
23-11-27 | 77.72 | -1.02% | 2,960,110 |
23-11-24 | 78.52 | +0.45% | 2,152,974 |
23-11-22 | 78.17 | +1.34% | 2,203,917 |
Delayed Quote Nasdaq, November 29, 2023 at 09:39 am EST
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2023-11-30
- Piper Sandler Healthcare Conference
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
78.18USD
Average target price
139.90USD
Spread / Average Target
+78.95%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-55.58% | 29 809 M $ | |
+66.84% | 40 404 M $ | |
+4.35% | 38 508 M $ | |
-24.52% | 28 695 M $ | |
+38.20% | 22 029 M $ | |
-31.26% | 20 250 M $ | |
+2.80% | 17 781 M $ | |
-16.76% | 10 827 M $ | |
-9.34% | 10 014 M $ | |
-24.53% | 9 752 M $ |